Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Mesenchymal stem cell therapy in acute kidney injury (AKI): review and perspectives

Full text
Author(s):
Savio-Silva, Christian [1] ; Soinski-Sousa, Poliana Evelyn [1] ; Balby-Rocha, Maria Theresa A. [1] ; Lira, Adyna de Oliveira [1] ; Rangel, Erika Bevilaqua [2, 1]
Total Authors: 5
Affiliation:
[1] Hosp Israelita Albert Einstein, Sao Paulo, SP - Brazil
[2] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, SP - Brazil
Total Affiliations: 2
Document type: Review article
Source: Revista da Associação Médica Brasileira; v. 66, n. 1, p. S45-S54, 2020.
Web of Science Citations: 0
Abstract

INTRODUCTION: Acute kidney injury (AKI) is highly prevalent today. It has a multifactorial aetiology and affects people of all ages, genders and ethnicities. Its treatment is essentially supportive of renal function substitution, so new treatment alternatives such as mesenchymal stem cell therapy (MSCs) should be investigated. METHODS: This review encompasses our understanding of the main mechanisms of action of MSCs in preclinical models of AKI by renal pedicle clamping ischemia-reperfusion, chemotherapy (cisplatin) and kidney transplantation in small and large animals, as well as outcomes in patients with AKI due to ischemia and kidney transplantation. RESULTS: Cellular therapy with MSCs has benefits in preclinical studies of AKI through various mechanisms, such as anti-inflammatory, antiapoptotic, oxidative anti-stress, antifibrotic, immunomodulatory and proangiogenic. In humans, MSC therapy is safe and effective. However, the challenges of MSC cell therapy include investigating protocols about the optimal dose of these cells, the route and frequency of appropriate administration, and the design of further biodistribution studies over a long follow-up period. In addition, a better understanding of molecular signalling and cellular interactions in the microenvironment of each organ and tissue is needed in order to define the best time to administer MSCs. Another challenge would be to mitigate the heterogeneity of the profile of cultured MSCs through preconditioning approaches. CONCLUSIONS: Cellular therapy with MSCs is very promising and should be part of the treatment of AKI patients in combination with other approaches already available, helping to accelerate recovery and/or slow the progression to chronic kidney disease. Randomized, multicentre controlled studies are needed to develop robust protocols that validate population-based cell therapy with MSCs. (AU)

FAPESP's process: 17/23195-2 - Mesenchymal stem cell therapy for halting the progression of acute and chronic kidney injury and in vivo modulate kidney-derived c-Kit stem cells
Grantee:Érika Bevilaqua Rangel
Support Opportunities: Regular Research Grants
FAPESP's process: 17/18072-9 - Glomerular mesangial cells mitochondrial dynamics alterations in hyperglycemia followed by mesenchymal stem cell therapy
Grantee:Christian Sávio Silva
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 18/24562-1 - Evaluation of oxidative stress and cell death of renal cells conditioned in vitro to Diabetic Renal Disease after treatment with bone marrow mesenchymal stem cells transfected with the Klotho gene
Grantee:Poliana Evelyn Soinski de Sousa
Support Opportunities: Scholarships in Brazil - Scientific Initiation